Ipsogen to present breast cancer program results at the upcoming 96th AACR annual meeting

Marseille, France, March 30, 2005 – Ipsogen SAS, a molecular diagnostic
company developing tests to improve disease management of cancer patients,
announced today that results concerning its breast cancer program have been
selected for presentation in a symposium session at the 2005 AACR Annual
Meeting in Anaheim, California.

The abstract titled “Utilisation of microarray technology to refine
molecular classes and improve clinical management of breast cancer,” is
available on the AACR website (aacr; abstract number: 2628)
and an
oral presentation has been scheduled on Monday, April 18, 2005 at 1:00 PM.
Further results from this program will be separately published in a peer
reviewed journal.

The results concern several gene expression signatures refining molecular
classes of breast cancer. Utilisation of these signatures together with
standard clinical parameters provides a unique combination discriminating
patients responding to standard anthracycline chemotherapy. The test was
validated in an independent cohort with patient samples from distinct
clinical sites. Ipsogen will also release data concerning translation of
these results to its Breast Cancer ProfileChipT, a simple diagnostic device
allowing straightforward utilisation of gene signatures in clinical
pathology laboratories. The study represents part of a research program
Ipsogen is conducting with the Institut Paoli-Calmettes (Marseille, France)
and in partnership with major French and US centres.

Based on these findings and ongoing clinical studies, Ipsogen believes
there is potential for applying this test to identify patients, at
diagnosis, with favorable outcome under standard anthracyclines
chemotherapy to avoid unnecessary intensification.

About Ipsogen

IPSOGEN is an emerging biotechnology company utilising advanced
technologies to analyse gene expression and to improve the disease
management of cancers. IPSOGEN addresses two main markets: (i) The
molecular diagnosis of cancer (i.e.; leukaemia, lymphomas, breast cancer)
to provide innovative diagnostic tools to clinical centres; (ii) the
optimisation of discovery and development of anti cancer drugs, to provide
pharmaceutical companies with high value information at the pre-clinical
and clinical stages, and accelerate drug development through biomarker
discovery and validation. Headquartered in Marseille, France, IPSOGEN has
global partnerships and markets its products worldwide.

This press release contains “forward-looking statements” as defined in the
US Private Securities Litigation Reform Act of 1995. No forward-looking
statement can be guaranteed, and actual results may differ materially from
those projected. Ipsogen SAS does not undertake any obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise. Forward-looking statements in
this document should be evaluated together with the many uncertainties that
affect the business of Ipsogen SAS, among others, the extent to which
Ipsogen’s technology platform can be used in large scale gene expression
analysis, uncertainty of market acceptance of Ipsogen’s technologies or
ability to compete against existing technologies.

Ipsogen: Vincent Fert, Chief Executive Officer – Tel +33 4 91293090 –

Global Headquarters
Luminy Biotech Entreprises
Case 923 – 163 Ave de Luminy
13288 Marseille
Tel: +33 4 91 29 30 90
Fax: +33 4 91 29 30 99

North America – Oncodiagnostics
Ipsogen, Inc
83 Maple Avenue
Connecticut 06095
Tel: +1 860 298 0234
Fax: +1 860 298 8586


This entry was posted in Uncategorized. Bookmark the permalink.